Jazz vaults into the cannabinoid field with $7.2B GW Pharma buyout
GW Pharma $GWPH, the UK biotech that caused a sensation of sorts with the approval of the world’s first cannabinoid med, is being bought out.
Jazz Pharmaceuticals came up with the winning number, agreeing to acquire GW for a total of $7.2 billion — $6.7 billion net of cash. GW agreed to a price of $200 cash and $20 in stock for the acquisition. This is the second biotech M&A deal of the week, which will likely portend more such deals to come.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.